Latest Healthcare It News

EBOS Group Limited’s interim results for H1 2025 reveal a notable decrease in revenue and profit compared to the prior year, yet the company maintains its interim dividend, signaling confidence despite headwinds.

EBOS Group Limited posted robust interim results for H1 FY25, with underlying EBITDA rising 7.1% excluding the Chemist Warehouse Australia contract, driven by strong organic growth and strategic investments. The company maintained its dividend and reiterated FY25 EBITDA guidance between $575 million and $600 million.

EBOS Group Limited posted a strong half-year performance with underlying EBITDA up 7.1% to $291 million, driven by growth in healthcare and animal care segments, while maintaining its interim dividend amid the loss of the Chemist Warehouse contract.

EBOS Group Limited has reported a 9% drop in revenue and an 18.9% fall in net profit for the first half of fiscal 2025, yet it maintains its interim dividend at 57 NZ cents per share.

Enlitic has announced a strategic collaboration with GE HealthCare to deploy AI-driven technology that will transform the migration of medical imaging data, promising faster, more secure transitions and enhanced data quality for healthcare providers worldwide.

Ansell Limited has updated its FY25 interim dividend details, confirming a payment of USD 0.222 per share with an AUD equivalent of 0.3486, payable on March 6, 2025.

Biome Australia Limited has reported its first-ever net profit of $433,395 for the half-year ended December 2024, alongside a 47.4% increase in revenue driven by strong sales of its Activated Probiotics.

Cardiex Limited has confirmed to the ASX that it holds no undisclosed information explaining the recent spike in its share price, affirming full compliance with continuous disclosure rules.

Recce Pharmaceuticals reports strong Phase II results for its RECCE® 327 topical gel, achieving a 93% efficacy rate in treating serious skin infections and setting the stage for accelerated Phase 3 trials.

GWA Group Limited reported a 1.9% revenue increase and a 3.2% rise in normalized EBIT for the half year ended December 2024, alongside a 7.1% lift in its interim dividend, reflecting disciplined execution despite tough market conditions.

GWA Group Limited reported a 1.9% revenue increase and a 3.2% rise in normalised EBIT for the half year ended December 2024, supported by strong cash flow and operational discipline. The company declared a fully franked interim dividend of 7.5 cents per share, up 7.1%.

Osteopore Limited has drawn down A$2 million from the first tranche of its redeemable convertible notes, using the proceeds to repay existing loans and support ongoing business activities.